Venezuela: An Investment Outlook Across Three Tracks (L.E.K. Consulting)

Summary

• Venezuela is reopening to investment, but the case differs by sector: pharma and medtech should move now, U.S. investors can lock optionality under GL 49A, and other sectors should wait for 2028-30.p.1
• The EMBI sovereign spread, still the highest in the world at approximately 6,400 basis points, is described as the practical thermometer for institutional stabilization.p.2
• Venezuela traded around 12,700 bps in late 2025 and compressed to roughly 6,400 bps by March 2026, a 50% narrowing.p.6
• Venezuela has been in selective default since 2017 on roughly $150 billion to $170 billion of external obligations.p.5
• Rystad estimates that maintaining production flat at 1.1 million bpd requires $53 billion of upstream capex over 15 years.p.5

Key insights

1. The sanctions regime never blocked medicine and medical devices; the barriers for pharma and medtech were macroeconomic and operational.p.3
2. FX repatriation should be planned as a 2027-28 issue, not a Day 1 certainty.p.4
3. OFAC General License 49A lets U.S. persons sign contingent agreements with PDVSA without deploying capital, which requires later specific OFAC authorization.p.4
4. Oil production fell from almost 3.5 million barrels per day in the late 1990s to under 1 million bpd by 2025.p.2
5. Venezuela is roughly 32 times Brazil and 10 times Argentina on the EMBI spread, and remains the highest-spread sovereign in the world.p.6
6. As of April 2026, no presidential election calendar has been published.p.5
7. Sustained production above 1.5 million bpd for three or more consecutive quarters would validate the operational and contractual architecture.p.5